Using shrinkage methods to estimate treatment effects in overlapping subgroups in randomized clinical trials with a time-to-event endpoint

TL;DR

This paper introduces shrinkage methods, including penalized and Bayesian approaches, to improve treatment effect estimation in overlapping subgroups of clinical trials with time-to-event data, addressing issues of small sample sizes and multiple testing.

Contribution

It develops a flexible Cox model with shrinkage techniques for overlapping subgroups and demonstrates improved estimation accuracy over standard methods.

Findings

Shrinkage estimators reduce mean-squared error compared to standard estimators.

Bayesian methods provide credible intervals for subgroup effects.

Shrinkage methods perform well in simulation studies, despite some bias.

Abstract

In randomized controlled trials, forest plots are frequently used to investigate the homogeneity of treatment effect estimates in subgroups. However, the interpretation of subgroup-specific treatment effect estimates requires great care due to the smaller sample size of subgroups and the large number of investigated subgroups. Bayesian shrinkage methods have been proposed to address these issues, but they often focus on disjoint subgroups while subgroups displayed in forest plots are overlapping, i.e., each subject appears in multiple subgroups. In our approach, we first build a flexible Cox model based on all available observations, including categorical covariates that identify the subgroups of interest and their interactions with the treatment group variable. We explore both penalized partial likelihood estimation with a lasso or ridge penalty for treatment-by-covariate interaction terms, and Bayesian estimation with a regularized horseshoe prior. One advantage of the Bayesian approach is the ability to derive credible intervals for shrunken subgroup-specific estimates. In a second step, the Cox model is marginalized to obtain treatment effect estimates for all subgroups. We illustrate these methods using data from a randomized clinical trial in follicular lymphoma and evaluate their properties in a simulation study. In all simulation scenarios, the overall mean-squared error is substantially smaller for penalized and shrinkage estimators compared to the standard subgroup-specific treatment effect estimator but leads to some bias for heterogeneous subgroups. We recommend that subgroup-specific estimators, which are typically displayed in forest plots, are more routinely complemented by treatment effect estimators based on shrinkage methods. The proposed methods are implemented in the R package bonsaiforest.